Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded Instituto De Neurología Cognitiva - INECO in Capital Federal, Argentina and Unidade Local de Saúde de Braga in Braga, Portugal, bringing the total number of study locations to 190. Hospital de Braga was removed from the location list.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page now indicates recruitment has closed and introduces new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study); the Intervention/Treatment heading formatting and the site version have been updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check31 days agoChange DetectedA new revision tag v3.5.5 was added and the previous v3.5.4 tag was removed. This indicates a minor update to the page's version metadata.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3, indicating a new platform release or patch rather than a change to the study data.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page revision label has been updated from v3.5.2 to v3.5.3. This reflects a site/version metadata refresh rather than a change to the clinical study information presented.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.